What is the management and treatment of falcine meningiomas?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Falcine Meningiomas: Epidemiology, Pathophysiology, Presentation, and Management

Epidemiology

Falcine meningiomas, together with parasagittal meningiomas, represent the second most common location of intracranial meningiomas, accounting for approximately 9% of all intracranial meningiomas. 1, 2

  • The middle third of the falx is the most frequently involved site (55-78% of cases), followed by the anterior third (26-31%) and posterior third (17-89%). 2
  • Most falcine meningiomas are benign (WHO grade 1), with transitional and meningothelial subtypes occurring in approximately 69% of patients. 2
  • High-grade (atypical or malignant) meningiomas are uncommon, occurring in only about 2% of cases in surgical series. 2

Pathophysiology

Falcine meningiomas are defined as meningiomas arising from the falx cerebri, covered by overlying brain parenchyma, and not involving the superior sagittal sinus. 1

  • These tumors originate from arachnoid cap cells within the falx and grow by displacing rather than invading adjacent brain tissue. 1
  • The growth pattern significantly influences surgical planning, with tumors classified by their relationship to the falx and degree of hemispheric involvement. 3
  • Calcifications are common, occurring in up to 50% of meningiomas, and may be more frequent in certain subtypes. 4

Clinical Presentation

Approximately one-third of patients with falcine meningiomas are asymptomatic at diagnosis, with tumors discovered incidentally on imaging. 2

Symptomatic Presentations:

  • Headaches are the most common symptom, occurring in approximately 27-28% of patients. 2
  • Seizures occur in approximately 14-15% of cases, related to cortical irritation from mass effect. 2
  • Lower extremity weakness presents in approximately 9-10% of patients, due to compression of the motor cortex along the interhemispheric fissure. 2
  • Progressive cognitive changes including abulia and behavioral changes may develop with large anterior falcine tumors. 5
  • Urinary incontinence can occur with bilateral frontal lobe involvement. 5
  • Symptoms typically develop gradually over months to years as the tumor slowly enlarges. 5

Diagnostic Evaluation

MRI with contrast is the gold standard for evaluating falcine meningiomas, revealing homogeneous dural-based enhancement with characteristic dural tail sign. 4, 6

Key Imaging Features:

  • Typical MRI findings include isointense or hypointense masses on T1-weighted images, hyperintense on T2-weighted images, with strong uniform contrast enhancement. 6
  • Coronal MRI sequences are essential for surgical planning, demonstrating tumor growth patterns and relationship to the falx. 3
  • CT scan provides complementary information, particularly for visualizing calcifications and hyperostosis. 6
  • Somatostatin receptor (SSTR) PET imaging should be considered when tumor extension is unclear or for differentiation between recurrence and post-treatment changes. 4, 6

Surgical Classification and Planning

A classification scheme based on tumor growth patterns on coronal MRI facilitates surgical planning and approach selection. 3

Classification System:

  • Type I (Hemispheroid): Tumors invaginating deeply into one hemisphere without shifting the falx—approach ipsilaterally via interhemispheric corridor. 3
  • Type II (Olive-shaped): Tumors shifting the falx substantially to the contralateral side—approach contralaterally via transfalcine route. 3
  • Type IIIA (Asymmetric dumbbell): Tumors extending into both hemispheres to different extents—approach from the side with smaller tumor burden. 3
  • Type IIIB (Symmetric dumbbell): Tumors extending equally into both hemispheres—approach from the non-dominant hemisphere. 3

Surgical Management

Complete surgical resection including removal of the dural attachment is the optimal treatment when feasible, with Simpson grade I resection achievable in 83-100% of cases in experienced centers. 7, 4, 3, 2

Surgical Approaches:

Interhemispheric Approach (Traditional):

  • Ipsilateral interhemispheric approach in supine or prone position is the standard technique for most falcine meningiomas. 2
  • This approach provides direct access to the falx and tumor attachment site. 2
  • Critical considerations include preservation of bridging veins, anterior cerebral artery branches, and cortical venous drainage. 1

Transcortical Approach (Alternative):

  • Transcortical resection through the superior frontal gyrus can be used as a safe alternative for large, bilobed falcine meningiomas. 5
  • This approach avoids risks of venous infarction and cortical injury associated with extensive interhemispheric dissection. 5
  • Particularly useful for giant tumors with significant bilateral involvement. 5

Endoscopic Contralateral Transfalcine Approach (Minimally Invasive):

  • Endoscopic contralateral keyhole approach with approximately 3 cm craniotomy offers less-invasive option for large falcine meningiomas. 8
  • Mean operation time of 265 minutes with Simpson grade I removal achievable in all cases. 8
  • Advantages include smaller craniotomy, shorter operation time, and reduced risk of venous complications. 8

Surgical Outcomes:

  • Gross total resection is achieved in 83-100% of cases in modern series. 3, 2
  • Mortality is essentially zero in contemporary surgical series. 3, 2
  • New or worsened neurological deficits occur in approximately 3% of patients postoperatively. 2
  • Perioperative complications including significant blood loss, venous injury, and infection occur in approximately 6% of cases. 2

Radiation Therapy

External beam radiation therapy is indicated for WHO grade 3 (malignant) meningiomas after surgery and for subtotally resected WHO grade 2 (atypical) meningiomas. 4

  • Adjuvant radiotherapy for incompletely resected benign meningiomas improves progression-free survival from approximately 50% to over 80% in adult series. 7
  • Stereotactic radiosurgery is effective for residual or recurrent meningiomas, particularly those <3 cm in diameter. 9
  • For larger meningiomas or those with pre-existing edema, fractionated stereotactic radiotherapy may be preferred. 9
  • The indication for adjuvant radiotherapy in adults with incompletely resected benign, grade I meningioma remains controversial. 7

Observation Strategy

Asymptomatic, incidentally discovered small falcine meningiomas (<30 mm) can be managed with observation and serial MRI surveillance. 4

  • Observation is particularly appropriate for elderly patients or those with significant comorbidities. 4
  • In adult series, cumulative relative survival for non-surgical management was 49% at 3 months and 25% at 15 years, compared to 93% at 3 months and 79% at 15 years for surgical patients. 7
  • Up to 20% of completely resected benign meningiomas recur within 25 years, indicating the need for lifelong follow-up. 7

Post-Treatment Surveillance

MRI without and with contrast every 6-12 months is recommended for follow-up of falcine meningiomas. 4, 9

  • After achieving stable disease status (typically after 5-10 years), follow-up intervals can be extended. 9
  • SSTR PET imaging may be useful in distinguishing tumor recurrence from post-treatment changes. 4
  • Clinical follow-up should include routine neurological examinations and assessment for signs of increased intracranial pressure. 9

Critical Surgical Considerations

Several anatomical factors must be carefully evaluated during surgical planning to minimize morbidity:

  • Bridging veins: Preservation is essential to prevent venous infarction. 1
  • Anterior cerebral artery branches: Must be identified and protected throughout resection. 1
  • Arterial feeders: Early identification and coagulation reduces intraoperative blood loss. 1
  • Superior sagittal sinus involvement: Must be assessed preoperatively as it changes surgical classification from falcine to parasagittal meningioma. 1
  • Modern surgical techniques including image-guided surgery (frameless stereotaxy) improve precision and may reduce surgical side effects. 4

Common Pitfalls to Avoid

  • Failing to recognize that not all enhancing dural-based lesions are meningiomas; brain metastases, gliomas, and primary CNS lymphoma can mimic meningiomas. 6
  • Underestimating blood loss risk, particularly with large or intraventricular tumors requiring high-dose steroids, head elevation, and close monitoring. 9, 6
  • Inadequate preoperative venous mapping can lead to inadvertent sacrifice of critical bridging veins causing venous infarction. 1
  • Incomplete dural resection increases recurrence risk; the dural attachment must be completely excised when feasible. 4

References

Research

Falcine meningiomas.

Handbook of clinical neurology, 2020

Research

Surgical management of falcine meningiomas: Experience of 95 patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2017

Research

A proposed scheme for the classification and surgical planning of falcine meningioma treatment.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2012

Guideline

Brain Meningioma Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Transcortical resection of a giant bilobed falcine meningioma.

British journal of neurosurgery, 2024

Guideline

Emergency Department Management of Suspected Meningioma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Torcular Meningioma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.